دورية أكاديمية
أعرض في EDS

Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma.

التفاصيل البيبلوغرافية
العنوان: Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma.
المؤلفون: Bacharier LB; Monroe Carell Jr Children's Hospital at Vanderbilt University Medical Center, Nashville, Tenn. Electronic address: leonard.bacharier@vumc.org., Pavord ID; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom., Maspero JF; Fundación CIDEA, Buenos Aires, Argentina., Jackson DJ; University of Wisconsin School of Medicine and Public Health, Madison, Wis., Fiocchi AG; Bambino Gesù Children's Hospital IRCCS, Rome, Italy., Mao X; Sanofi, Bridgewater, NJ., Jacob-Nara JA; Sanofi, Bridgewater, NJ., Deniz Y; Regeneron Pharmaceuticals Inc, Tarrytown, NY., Laws E; Sanofi, Bridgewater, NJ., Mannent LP; Sanofi, Chilly-Mazarin, France., Amin N; Sanofi, Bridgewater, NJ., Akinlade B; Sanofi, Bridgewater, NJ., Staudinger HW; Sanofi, Bridgewater, NJ., Lederer DJ; Regeneron Pharmaceuticals Inc, Tarrytown, NY., Hardin M; Sanofi, Cambridge, Mass.
المصدر: The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2024 Jul; Vol. 154 (1), pp. 101-110. Date of Electronic Publication: 2024 Jan 23.
نوع المنشور: Journal Article; Randomized Controlled Trial
اللغة: English
بيانات الدورية: Publisher: Mosby Country of Publication: United States NLM ID: 1275002 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6825 (Electronic) Linking ISSN: 00916749 NLM ISO Abbreviation: J Allergy Clin Immunol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: St Louis, Mosby.
مواضيع طبية MeSH: Asthma*/drug therapy , Asthma*/diagnosis , Asthma*/metabolism , Eosinophils*/immunology , Biomarkers* , Nitric Oxide*/metabolism , Antibodies, Monoclonal, Humanized*/therapeutic use, Humans ; Child ; Male ; Female ; Prognosis ; Fractional Exhaled Nitric Oxide Testing ; Leukocyte Count ; Anti-Asthmatic Agents/therapeutic use ; Exhalation
مستخلص: Background: Blood eosinophils and fractional exhaled nitric oxide (Feno) are prognostic biomarkers for exacerbations and predict lung function responses to dupilumab in adolescents and adults with asthma.
Objective: We evaluated the relationship between baseline blood eosinophils and Feno and response to dupilumab in children with asthma.
Methods: Children aged 6 to 11 years with uncontrolled moderate-to-severe asthma (n = 408) were randomized to receive dupilumab 100/200 mg by body weight or volume-matched placebo every 2 weeks for 52 weeks. Annualized exacerbation rate (AER) reduction and least squares mean change in prebronchodilator percent predicted forced expiratory volume in 1 second (ppFEV 1 ) at week 12 were assessed according to cutoff baseline levels for Feno (<20 ppb vs ≥20 ppb) and blood eosinophil count (<150, ≥150 to <300, ≥300 to <500, and ≥500 cells/μL). Quadrant analyses in populations defined by biomarker thresholds and spline models across continuous end points assessed the relationship with Feno and eosinophil count. Interaction testing evaluated the independent roles of Feno and blood eosinophils as predictive markers.
Results: Exacerbation risk and magnitude of AER reduction increased in subgroups with higher baseline biomarker levels. Quadrant analyses revealed that disease of patients with either elevated Feno or eosinophil counts demonstrated a clinical response to dupilumab. Interaction testing indicated blood eosinophil counts or Feno independently added value as predictive biomarkers.
Conclusions: In children with uncontrolled moderate-to-severe asthma, blood eosinophil counts and Feno are clinically relevant biomarkers to identify those at risk for asthma exacerbations, as well as those with disease with clinical response to dupilumab.
Trial Registration: Liberty Asthma VOYAGE ClinicalTrials.gov NCT02948959.
(Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
فهرسة مساهمة: Keywords: Asthma; biomarkers; blood eosinophils; childhood; fractional exhaled nitric oxide (Feno); pediatric; predictive; prognostic
سلسلة جزيئية: ClinicalTrials.gov NCT02948959
المشرفين على المادة: 0 (Biomarkers)
31C4KY9ESH (Nitric Oxide)
420K487FSG (dupilumab)
0 (Antibodies, Monoclonal, Humanized)
0 (Anti-Asthmatic Agents)
تواريخ الأحداث: Date Created: 20240125 Date Completed: 20240706 Latest Revision: 20240709
رمز التحديث: 20240710
DOI: 10.1016/j.jaci.2023.09.044
PMID: 38272375
قاعدة البيانات: MEDLINE
الوصف
تدمد:1097-6825
DOI:10.1016/j.jaci.2023.09.044